Real-time enrollment status for this high risk smoldering multiple myeloma (hr-smm) clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 12:02 PM UTC
| NCT Number | NCT07393282 |
| Recruiting Status | Recruiting |
| Condition | High Risk Smoldering Multiple Myeloma (HR-SMM) |
| Phase | PHASE3 |
| Target Enrollment | 270 participants |
| Active Locations | 8 sites in the US |
| Sponsor | Regeneron Pharmaceuticals |
| Last Updated on CT.gov | October 7, 2026 (1 week ago) |
As of October 15, 2026: Clinical trial NCT07393282 is currently recruiting participants. This phase3 study for high risk smoldering multiple myeloma (hr-smm) is actively seeking new participants at 8 locations across the United States. The study is sponsored by Regeneron Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07393282 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07393282 was last updated 1 week ago (October 7, 2026). HelloStudys verifies this status automatically.